Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
November 30, 2023
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 9, 2023
Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
November 8, 2023
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
November 2, 2023
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
November 1, 2023
Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
October 9, 2023
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
October 9, 2023
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer
September 25, 2023
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
September 21, 2023
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference
September 15, 2023
Displaying 1 - 10 of 39